Jonathan E. Knikman
YOU?
Author Swipe
View article: Severe fluoropyrimidine toxicity in older adults with cancer with <i>DPYD</i> wild type
Severe fluoropyrimidine toxicity in older adults with cancer with <i>DPYD</i> wild type Open
Background Despite the implementation of DPYD genotype‐guided dosing, approximately 1 in 3 patients receiving fluoropyrimidine‐containing chemotherapy continues to experience severe toxicity. While clinical studies have demonstrated a favo…
View article: Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD Open
View article: A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens
A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens Open
DPYD ‐guided dosing has improved the safety of fluoropyrimidine‐based chemotherapy in recent years. However, severe toxicity remains in ~ 23% of patients not carrying DPYD variant alleles treated with capecitabine. Therefore, we developed …
View article: Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis Open
Outcome of DPYD variant allele carriers treated with dose-individualized fluoropyrimidine therapy.
View article: Response to “Plasma Uracil as a <scp>DPD</scp> Phenotyping Test: Pre‐analytical Handling Matters”
Response to “Plasma Uracil as a <span>DPD</span> Phenotyping Test: Pre‐analytical Handling Matters” Open
View article: Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study Open
In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe fluoropyrimidine‐related toxicity. Extensively clinically validated DPYD genotyping tests are available to identify patients at risk of severe to…
View article: Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? Open
Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although most often well tolerated, severe toxicity is encountered in ~ 20–30% of the patients. Individualized dosing for these patients can reduce the in…
View article: A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices
A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices Open
The bioanalysis of the oral anticancer drug capecitabine and its metabolites has been investigated extensively over the past years. This paper reviews methods for the bioanalysis of capecitabine and its metabolites. The focus of this revie…